Status:
COMPLETED
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin com...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Treated with oral anti-diabetic (OAD) drugs for at least 3 months
- Treated with one or more OAD and in moderate to poor glycemic control
- Body Mass Index (BMI) less than or equal to 45.0 kg/m2
Exclusion
- Treatment with insulin within the last three months prior to the trial except due to intercurrent illness, at the discretion of the Investigator
- Any serious medical condition
- Treatment with any drug that could interfere with glucose level
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
576 Patients enrolled
Trial Details
Trial ID
NCT00333151
Start Date
May 1 2006
End Date
August 1 2007
Last Update
January 25 2017
Active Locations (89)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Goodyear, Arizona, United States, 85395
2
Novo Nordisk Investigational Site
Colton, California, United States, 92324
3
Novo Nordisk Investigational Site
Concord, California, United States, 94520
4
Novo Nordisk Investigational Site
Escondido, California, United States, 92025